MehtaPKGriendlingKK. Angiotensin II Cell Signaling. Physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol2007; 92: C82–C97.
2.
BerridgeMJ. Inositol trisphosphate and calcium signalling. Nature1993; 361: 315–325.
3.
TouyzRM. Role of angiotensin II in regulating vascular structural and functional changes in hypertension. Curr Hypertens Rep2003; 5: 155–164.
4.
Ushio-FukaiMGriendlingKKAkersMLyonsPRAlexanderRW. Temporal dispersion of activation of phospholipase C-beta1 and -gamma isoforms by angiotensin II in vascular smooth muscle cells. Role of alphaq/11, alpha12, and beta gamma G protein subunits. J Biol Chem1998; 273: 19772–19777.
5.
TabetFSchiffrinELCalleraGE. Redox-sensitive signaling by angiotensin ii involves oxidative inactivation and blunted phosphorylation of protein tyrosine phosphatase SHP-2 in vascular smooth muscle cells from SHR. Circ Res2008; 103: 149–158.
6.
LoirandGGuerinPPacaudP. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res2006;98: 322–334.
7.
CalòLAPessinaAC. RhoA/Rho-kinase pathway: much more than just a modulation of vascular tone. Evidence from studies in humans. J Hypertens2007; 25: 259–264.
8.
WennerbergKDerCJ. Rho-family GTPases: it’s not only Rac and Rho (and I like it). J. Cell Sci2004; 117: 1301–1312.
9.
SiderovskiD PWillardFS. The GAPs, GEFs, and GDIs of heterotrimeric G-protein alpha subunits. Int J Biol Sci2005; 1: 51–66.
10.
WuertzMCLorinczAVettelCThomasMAWielandTLutzS. p63RhoGEF – a key mediator of angiotensin II dependent signaling and processes in vascular smooth muscle cells. FASEB J2010; 24, 4865–4876.
11.
ShankaranarayananABoguthCALutzS. Galpha q allosterically activates and relieves autoinhibition of p63RhoGEF. Cell Signal2010; 22: 1114–1123.
12.
GuilluyCBrégeonJToumaniantzG. The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure. Nat Med2010; 16: 183–190.
13.
NaesensMSteelsPVerberckmoesRVanrenterghemYKuypersD. Bartter’s and Gitelman’s Syndromes: From gene to clinic. Nephron Physiol2004; 96: 65–78.
14.
CalòLA. Vascular tone control in humans: the utility of studies in Bartter’s/Gitelman’s syndromes. Kidney Int2006; 69: 963–966.
15.
CalòLAPagninEDavisPA. Increased expression of regulator of G protein signaling-2 (RGS-2) in Bartter’s/Gitelman’s syndrome. A role in the control of vascular tone and implication for hypertension. J Clin Endocrinol Metab2004; 89: 4153–4157.
16.
WielandTLutzSChidiacP. Regulators of G protein signaling: a spotlight on emerging functions in the cardiovascular system. Curr Opin Pharmacol2007; 7: 1–7.
17.
ShankaranarayananAThalDMTesmerVM. Assembly of high order G alpha q-effector complexes with RGS proteins. J Biol Chem2008; 283: 34923–34934.
18.
CalòLAPagninECeolottoG. Silencing regulator of G protein signaling-2 (RGS-2) increases angiotensin II signaling: insights into hypertension from findings in Bartter’s/Gitelman’s syndromes. J Hypertens2008; 26: 938–945.
19.
SempliciniALenziniLSartoriM. Reduced expression of regulator of G protein signaling-2 in hypertensive patients increases calcium mobilization and ERK1/2 phosphorylation induced by angiotensin II. J Hypertens2006; 24: 1115–1124.
20.
CalòLASchiavoSDavisPA. Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: implications for hypertension. J Hypertens2010; 28: 111–118.
21.
PagninESempliciniASartoriMPessinaACCalòLA. Reduced mRNA and protein content of Rho guanine nucleotide exchange factor (RhoGEF) in Bartter’s and Gitelman’s syndromes: relevance for the pathophysiology of hypertension. Am J Hypertens2005; 18: 1200–1205.
22.
PagninEDavisPASartoriMSempliciniAPessinaACCalòLA. Rho kinase and PAI-1 in Bartter’s/Gitelman’s syndromes: relationship to angiotensin II signaling. J Hypertens2004; 22: 1963–1969.
23.
CalòLSartoreGBassiA. Reduced susceptibility of low density lipoprotein to oxidation in patients with overproduction of nitric oxide (Bartter’s and Gitelman’s syndrome). J Hypertens1998; 16: 1001–1008.
24.
CalòLAPagninEDavisPASartoriMSempliciniA. Oxidative stress related factors in Bartter’s and Gitelman’s syndromes: relevance for angiotensin II signalling. Nephrol Dial Transplant2003; 18: 1518–1525.
25.
CalòLAPuatoMSchiavoS. Absence of vascular remodelling in a high angiotensin-II state (Bartter’s and Gitelman’s syndromes): implications for angiotensin IIsignalling pathways. Nephrol Dial Transplant2008: 23: 2804–2809.
26.
CalòLAMontisciRScognamiglioR. High angiotensin II state without cardiac remodeling (Bartter’s and Gitelman’s syndromes). Are angiotensin II type 2 receptors involved?J Endocrinol Invest2009; 32: 832–836.
27.
MogiMIwaiMHoriuchiM. Emerging concepts of regulation of angiotensin II receptors: new players and targets for traditional receptors. Arterioscler Thromb Vasc Biol2007; 27: 2532–2539.
28.
NouetSNahmiasC. Signal transduction from the angiotensin II AT2 receptor. Trends Endocrinol Metab2000; 11: 1–6.
29.
CareyRM. Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age. Hypertension2005; 45: 840–844.
30.
SavoiaCTabetFYaoGSchiffrinELTouyzRM. Negative regulation of RhoA/Rho kinase by angiotensin II type 2 receptor in vascular smooth muscle cells: role in angiotensin II-induced vasodilation in stroke-prone spontaneously hypertensive rats. J Hypertens2005; 23: 1037–1045.
31.
SiragyHM. Evidence for benefits of angiotensin receptor blockade beyond blood pressure control. Curr Hypertens Rep2008; 10: 261–267.
